Active Ingredient History
Exenatide (exendin-4) is sold under the brand name BYETTA to improve glycemic control in people with type 2 diabetes mellitus. Exenatide is a glucagon-like peptide 1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion by the pancreatic beta cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. The drug also moderates peak serum glucagon levels during hyperglycemic periods following meals but does not interfere with glucagon release in response to hypoglycemia. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Acute Coronary Syndrome (Phase 4)
Alcohol-Induced Disorders (Phase 2)
Alcoholism (Phase 2)
Atherosclerosis (Phase 4)
Autoimmune Diseases (Phase 1/Phase 2)
Blood Glucose (Phase 4)
Bone Remodeling (Phase 4)
Brain Injuries (Phase 4)
Burns (Phase 2/Phase 3)
Cardiovascular Diseases (Phase 4)
Cocaine-Related Disorders (Phase 1/Phase 2)
Cognition Disorders (Phase 3)
Coronary Artery Disease (Phase 3)
Coronary Restenosis (Phase 4)
Craniopharyngioma (Phase 3)
Deficiency Diseases (Phase 4)
Diabetes Complications (Phase 2)
Diabetes, Gestational (Phase 4)
Diabetes Insipidus, Neurogenic (Phase 4)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 1 (Phase 4)
Diabetic Nephropathies (Phase 4)
Diet, Ketogenic (Phase 4)
Endothelium (Phase 4)
Fatty Liver (Phase 4)
Glucose Intolerance (Phase 4)
Healthy Volunteers (Phase 4)
Heart Failure (Phase 4)
Heart Failure, Diastolic (Phase 4)
HIV (Phase 4)
Hyperglycemia (Phase 4)
Hypertrophy, Left Ventricular (Phase 3)
Hypoglycemia (Phase 2/Phase 3)
Hypopituitarism (Phase 4)
Hypothalamic Diseases (Phase 4)
Inflammation (Phase 1/Phase 2)
Insulin Resistance (Phase 4)
Ischemic Stroke (Phase 2)
Kidney Diseases (Phase 4)
Metabolic Syndrome (Phase 3)
Multiple System Atrophy (Phase 2)
Myocardial Infarction (Phase 4)
Non-alcoholic Fatty Liver Disease (Phase 4)
Obesity (Phase 4)
Obesity, Morbid (Phase 2/Phase 3)
Organ Dysfunction Scores (Phase 1/Phase 2)
Overweight (Phase 4)
Parkinson Disease (Phase 3)
Pediatric Obesity (Phase 3)
Pituitary Diseases (Phase 4)
Polycystic Ovary Syndrome (Phase 4)
Prediabetic State (Phase 4)
Psychological Distress (Phase 2/Phase 3)
Psychology, Clinical (Phase 4)
Psychotic Disorders (Phase 4)
Quality of Life (Phase 2/Phase 3)
Renal Insufficiency (Phase 1)
Renal Insufficiency, Chronic (Phase 3)
Schizophrenia (Phase 4)
Shock, Septic (Phase 1/Phase 2)
Short Bowel Syndrome (Phase 4)
Smoking Cessation (Phase 1/Phase 2)
Social Isolation (Phase 4)
Spinal Cord Injuries (Phase 4)
Stroke (Phase 2)
Weight Gain (Phase 4)
Weight Loss (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue